After Ether's price dropped 15% to around $2,000, a large investor (whale) purchased 6,087 ETH at $2,031 each, spending about $12.36 million. This follows the same whale's sale of 5,368 ETH at $2,739 each on September 22, which brought in roughly $14.7 million. The recent purchase price was about 26% lower than the earlier sale price, indicating the whale is buying back in at a discount after the price decline. This activity highlights strategic trading around Ether's price fluctuations.
Regarding the whale's recent Ether transactions, here is Pluang's market snapshot as of Nov 12, 2026 05:22 WIB: Out of 50 major cryptocurrencies priced on Pluang, 27 rose and 22 fell today. Notable movers include UNI at Rp117.501 with a 1-day change of -3.70% and a Pluang order activity of 75% Sell / 25% Buy, FIL at Rp13.938 with +2.97% and 0% Sell / 100% Buy, and XLM at Rp2.699 with +2.90% and 5% Sell / 95% Buy. The most notable figure is FIL's 100% buy order activity on Pluang.
Ashland Inc.'s board of directors declared a quarterly cash dividend of $0.42 per share, payable on December 15, 2026, to shareholders of record as of December 1, 2026. This dividend reflects the company's ongoing commitment to returning value to sha...
AeroVironment secured a $405 million international order for its LOCUST X3 high-energy laser weapon systems, enhancing counter-drone defense capabilities in the Middle East amid rising regional security threats. Following the announcement, AeroVironm...
Vestas Wind Systems reported Q3 2026 earnings per share of $0.13 and revenue of $6.34 billion, both below analyst expectations. The company's profit was impacted by weak sales volume and a broken turbine blade. Following the earnings miss, Vestas' sh...
The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...
DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...
